Fig. 4.
a, b Tumor blood vessel perfusion assay using FITC-dextran in vivo. Following 3 weeks of treatment with PRIMA-1 and 2aG4, tumor-bearing animals were injected (iv) with 0.2 ml of 25 mg/ml FITC-dextran (molecular weight 2,000,000) for 20 min. Tumors and whole blood were collected, processed, and centrifuged. Fluorescence was measured in supernatant from tumor tissue and whole body plasma. The ratio of tumor/plasma fluorescence reflects the extent of tumor perfusion. Samples were analyzed from four animals per group. Points indicate mean volumes in each group of mice, bars indicate SEM. *P < 0.05 compared with the C44 group, **P < 0.05 compared with the C44, PRIMA-1, and 2aG4 groups